Aruna D. Pradhan, MD, MPH, MSc
Associate Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women’s Hospital
apradhan@bwh.harvard.edu
Dr. Pradhan joined the faculty in 2005. She has joint appointments in the Division of Preventive Medicine at the Brigham and Women’s Hospital and Cardiovascular Medicine Division at the Veteran’s Administration Hospital, West Roxbury Campus. Her research interests span the related areas of inflammation, diabetes, and peripheral artery disease. Her early work demonstrated a strong link between subclinical inflammation and the development of diabetes. She continued this line of research as the Principal Investigator of the LANCET clinical trial which studied insulin therapy as a strategy to reduce inflammation among patients with diabetes during the initial stage of this disease. Other research activities pertain to the role of adipokines and other biologic markers having combined metabolic and inflammatory functions in the pathogenesis of diabetes and its vascular complications. As a recipient of a career development award from the National Heart, Lung, and Blood Institute to study risk factors for peripheral artery disease, Dr. Pradhan is also keenly interested in evaluating risk factors and underlying mechanisms that distinguish individuals at high risk for future coronary artery disease as compared to lower extremity artery disease. Dr. Pradhan is also a recipient of NIH funding to evaluate mechanisms of statin-associated diabetes in the JUPITER trial.
Dr. Pradhan completed her cardiovascular medicine fellowship at the Brigham and Women’s Hospital and continues her clinical activities as an echocardiographer and clinical cardiologist at the VA Boston Healthcare System, West Roxbury Campus.
MPH: Johns Hopkins University School of Hygiene and Public Health
MD: Georgetown University School of Medicine
MSc: Harvard School of Public Health
Full Listing of Publications
- Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial November 3, 2024CONCLUSIONS: Each of insulin, C-peptide, IRS, and HbA1c were associated with incident T2D with the strongest association noted for HbA1c. While HbA1c was significantly associated with CVD risk, a novel IRS appears to be associated with CHD risk. Neither vitamin D nor n-3 FA modified the associations between these biomarkers and cardiometabolic outcomes.Frank Qian
- Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT July 17, 2024No abstractLucas L Marinho
- C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations May 23, 2023Anti-inflammatory drugs reduce the risk of cardiovascular events in patients with coronary artery disease (CAD), but less is known about the relation between inflammation and outcomes in patients with cerebrovascular disease (CeVD), peripheral artery disease (PAD), and abdominal aortic aneurysm (AAA). This study assessed the association between C-reactive protein (CRP) and clinical outcomes in patients […]Pascal M Burger
- Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies: JACC Focus Seminar 3/3 April 19, 2023Triglyceride-rich lipoproteins (TRLs) are a source of residual risk in patients with atherosclerotic cardiovascular disease, and are indirectly correlated with triglyceride (TG) levels. Previous clinical trials studying TG-lowering therapies have either failed to reduce major adverse cardiovascular events or shown no linkage of TG reduction with event reduction, particularly when these agents were tested on […]Waqas A Malick
- Coronary Flow Reserve, Inflammation, and Myocardial Strain: The CIRT-CFR Trial March 13, 2023Inflammation is a key determinant of cardiovascular outcomes, but its role in heart failure is uncertain. In patients with cardiometabolic disease enrolled in the prospective, multicenter ancillary study of CIRT (Cardiovascular Inflammation Reduction Trial), CIRT-CFR (Coronary Flow Reserve to Assess Cardiovascular Inflammation), impaired coronary flow reserve was independently associated with increased inflammation and myocardial strain […]Viviany R Taqueti